Wholesale Erbitux 500 mg for US Clinics | Ernest Oncology India Supply

Erbitux 500 mg Injection: High-Potency EGFR Targeted Therapy for Advanced Oncology

Are you searching for a reliable Erbitux 500 mg injection exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a high-authority global supplier and bulk distributor of advanced monoclonal antibodies. We manage a robust, cold-chain-integrated supply chain serving the USA, UK, Australia, and South Africa, ensuring that high-dose EGFR-targeted treatments reach medical centers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Erbitux 500 mg?

Erbitux 500 mg Injection is a recombinant human/mouse chimeric monoclonal antibody containing the active ingredient Cetuximab. This high-dose formulation is designed for precision oncology, specifically targeting the Epidermal Growth Factor Receptor (EGFR).

For international B2B procurement, Erbitux 500 mg (supplied as a 500 mg/100 ml solution for infusion) is the preferred format for intensive induction cycles and large-scale hospital requirements, offering a concentrated solution for treating specific solid tumors.

Primary Therapeutic Indications

Erbitux 500 mg is clinically utilized globally for the following:

1. Metastatic Colorectal Cancer (mCRC): For patients with EGFR-expressing, RAS wild-type tumors, utilized in combination with chemotherapy or as a single agent.

2. Head and Neck Cancer (SCCHN):

• Locally Advanced: Used in combination with radiation therapy.

• Metastatic/Recurrent: Used in combination with platinum-based therapy.

• Refractory: As a single agent for patients failing previous platinum-based regimens.

Mechanism of Action: How Cetuximab Inhibits Tumor Growth

Erbitux 500 mg works through a multi-step biological pathway:

• EGFR Competitive Inhibition: The antibody binds specifically to the extracellular domain of the EGFR, blocking the binding of endogenous ligands like EGF.

• Signaling Pathway Blockade: By preventing ligand binding, it shuts down the internal signaling (PI3K/Akt and MAPK pathways) that drives cell proliferation, survival, and angiogenesis.

• Inducing Cell Stasis: It halts the cell cycle in the G1 phase, leading to tumor growth inhibition.

• Immune System Engagement: It stimulates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), signaling the body’s natural killer (NK) cells to destroy the bound cancer cells.

Administration and Clinical Safety

• Administration: Must be administered as an intravenous (IV) infusion via an infusion pump or gravity drip by qualified medical personnel.

• Pre-medication Protocol: Patients must be pre-medicated with an antihistamine (H1 antagonist) to mitigate infusion-related reactions.

• Cold-Chain Integrity: Requires strict storage at 2°C to 8°C (36°F to 46°F). Do not freeze or shake the vial.

• Key Monitoring:

• Dermatologic Reactions: Acneiform rash is common and should be managed by specialists.

• Electrolyte Balance: Regular monitoring of magnesium, calcium, and potassium levels is recommended.

• RAS Mutation Status: Testing for KRAS and NRAS mutations is essential before initiating mCRC therapy.

Why Source Erbitux from Ernest Oncology?

• Authentic Indian Exporter: We provide direct access to genuine oncology inventory, ensuring 100% product authenticity and competitive wholesale pricing for the USA, UK, Australia, and South Africa.

• Validated Cold-Chain Export: We utilize advanced thermal shipping solutions and real-time temperature data loggers to ensure Erbitux remains within the required range throughout transit.

• Regulatory Support: Full B2B documentation provided, including GMP compliance certificates, batch-specific COAs, and all necessary export permits.

• Bulk Supply Stability: We specialize in large-scale fulfillment for hospital groups, government tenders, and regional oncology distributors.